daptomycin

Summary

Summary: A lipopeptide antibiotic that inhibits gram-positive bacteria.

Top Publications

  1. pmc Genetic basis for daptomycin resistance in enterococci
    Kelli L Palmer
    Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 55:3345-56. 2011
  2. pmc Genetic basis for in vivo daptomycin resistance in enterococci
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    N Engl J Med 365:892-900. 2011
  3. pmc Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
  4. pmc Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
  5. pmc Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus
    Anton Y Peleg
    Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia
    PLoS ONE 7:e28316. 2012
  6. pmc Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
  7. pmc An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
  8. ncbi Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:143-9. 2007
  9. pmc Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
  10. pmc Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, Torrance, California 90502, USA
    Antimicrob Agents Chemother 53:2312-8. 2009

Detail Information

Publications281 found, 100 shown here

  1. pmc Genetic basis for daptomycin resistance in enterococci
    Kelli L Palmer
    Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 55:3345-56. 2011
    ..The lipopeptide antibiotic daptomycin is approved to treat Gram-positive bacterial infections, including those caused by enterococci...
  2. pmc Genetic basis for in vivo daptomycin resistance in enterococci
    Cesar A Arias
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX 77030, USA
    N Engl J Med 365:892-900. 2011
    b>Daptomycin is a lipopeptide with bactericidal activity that acts on the cell membrane of enterococci and is often used off-label to treat patients infected with vancomycin-resistant enterococci...
  3. pmc Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus
    Jared A Silverman
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts 02421, USA
    Antimicrob Agents Chemother 47:2538-44. 2003
    The objective of this study was to further elucidate the role of membrane potential in the mechanism of action of daptomycin, a novel lipopeptide antibiotic...
  4. pmc Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization
    Arunachalam Muthaiyan
    Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790 4120, USA
    Antimicrob Agents Chemother 52:980-90. 2008
    b>Daptomycin is a lipopeptide antibiotic that has recently been approved for treatment of gram-positive bacterial infections. The mode of action of daptomycin is not yet entirely clear...
  5. pmc Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus
    Anton Y Peleg
    Department of Microbiology, School of Biomedical Sciences, Monash University, Melbourne, Australia
    PLoS ONE 7:e28316. 2012
    b>Daptomycin remains one of our last-line anti-staphylococcal agents. This study aims to characterize the genetic evolution to daptomycin resistance in S. aureus.
  6. pmc Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus
    Lisa Friedman
    Cubist Pharmaceuticals, Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 50:2137-45. 2006
    b>Daptomycin is a lipopeptide antibiotic with potent activity against gram-positive bacteria...
  7. pmc An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 54:5222-33. 2010
    ..the establishment of a Staphylococcus aureus laboratory strain, 10 3d1, having reduced susceptibility to daptomycin and heterogeneous vancomycin-intermediate S. aureus (VISA) phenotype...
  8. ncbi Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004)
    Douglas J Biedenbach
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 30:143-9. 2007
    ..Program during 2003-2004 to determine their susceptibility to several antimicrobial classes, including daptomycin. Daptomycin, vancomycin and teicoplanin minimum inhibitory concentrations (MICs) and minimum bactericidal ..
  9. pmc Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus
    Longzhu Cui
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo, Japan 113 8421
    Antimicrob Agents Chemother 50:1079-82. 2006
    We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA)...
  10. pmc Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus
    Nagendra N Mishra
    Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor University of California at Los Angeles Medical Center, 1124 West Carson St, Torrance, California 90502, USA
    Antimicrob Agents Chemother 53:2312-8. 2009
    Our previous studies of clinical daptomycin-resistant (Dap(r)) Staphylococcus aureus strains suggested that resistance is linked to the perturbations of several key cell membrane (CM) characteristics, including the CM order (fluidity), ..
  11. pmc Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin
    Daniel J Skiest
    Baystate Medical Center, Division of Infectious Diseases, 759 Chestnut St, Springfield, MA 01199, USA
    J Clin Microbiol 44:655-6. 2006
    b>Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA)...
  12. pmc Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation
    Ute Bertsche
    Interfacultary Institute of Microbiology and Infection Medicine, Microbial Genetics, University of Tubingen, Auf der Morgenstelle 28, 72076 Tubingen, Germany
    Antimicrob Agents Chemother 55:3922-8. 2011
    Cell wall thickening is a common feature among daptomycin-resistant Staphylococcus aureus strains. However, the mechanism(s) leading to this phenotype is unknown...
  13. pmc Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms
    Soo Jin Yang
    Los Angeles Biomedical Research Institute, Torrance, California 90502, USA
    Antimicrob Agents Chemother 54:3079-85. 2010
    The mechanism(s) of daptomycin (DAP) resistance (DAPr) is incompletely defined...
  14. pmc Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus
    Soo Jin Yang
    Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 90502, USA
    J Infect Dis 200:1916-20. 2009
    ..we investigated the transcriptional profiles of the mprF and dlt genes in the context of cell-surface charge and daptomycin nonsusceptibility...
  15. pmc Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 48:4665-72. 2004
    ..Staphylococcus aureus (MSSA and MRSA, respectively) on the activities of nafcillin, linezolid, vancomycin, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model with simulated endocardial ..
  16. pmc Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding
    Tiffanny Jones
    Los Angeles Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 225, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 52:269-78. 2008
    Increasingly frequent reports have described the in vivo loss of daptomycin susceptibility in association with clinical treatment failures. The mechanism(s) of daptomycin resistance is not well understood...
  17. pmc Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis
    Kathleen Julian
    Penn State Milton S Hershey Medical Center, Room C6833, BMR Bldg, Mailcode H036, 500 University Dr, Hershey, PA 17033, USA
    Antimicrob Agents Chemother 51:3445-8. 2007
    We analyzed the emergence of daptomycin nonsusceptibility in a patient with persistent vancomycin-intermediate Staphylococcus aureus (VISA) bacteremia...
  18. pmc Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure
    Susan Boyle-Vavra
    Department of Pediatrics, University of Chicago, KCBD 4152, 900 E 57th Street, Chicago, IL 60657, USA
    Antimicrob Agents Chemother 55:2018-25. 2011
    We describe here a clinical daptomycin treatment failure in a patient with recurrent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in whom daptomycin was administered after a failed empirical treatment course with ..
  19. doi Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases
    Becky A Miller
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
    Clin Infect Dis 50:e63-8. 2010
    We describe 3 cases of daptomycin-induced pulmonary toxic effects that are consistent with drug-induced acute eosinophilic pneumonia...
  20. pmc VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus
    Shrenik Mehta
    Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA
    Antimicrob Agents Chemother 56:92-102. 2012
    b>Daptomycin (DAP) is a new class of cyclic lipopeptide antibiotic highly active against methicillin-resistant Staphylococcus aureus (MRSA) infections...
  21. pmc In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates
    Nagendra N Mishra
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, Bldg RB2, Room 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 55:4012-8. 2011
    ..that methicillin-resistant Staphylococcus aureus (MRSA) isolates developing reduced susceptibilities to daptomycin (DAP; a calcium-dependent molecule acting as a cationic antimicrobial peptide [CAP]) may also coevolve reduced ..
  22. ncbi Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York, USA
    Clin Infect Dis 50:1568-74. 2010
    The objective of this analysis was to evaluate the relationship between daptomycin exposure and the probability of an elevation in the creatine phosphokinase (CPK) level (hereafter, "CPK elevation") in patients with Staphylococcus aureus ..
  23. ncbi Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia
    Peter E Pertel
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 46:1142-51. 2008
    We sought to compare daptomycin with ceftriaxone for the treatment of patients with community-acquired pneumonia (CAP).
  24. pmc Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus
    Helio S Sader
    JMI Laboratories, 345 Beaver Kreek Centre, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:3162-5. 2009
    Vancomycin and daptomycin MIC results for 1,800 randomly selected oxacillin (methicillin [meticillin])-resistant Staphylococcus aureus (MRSA) bloodstream isolates from nine U.S...
  25. pmc Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype
    Ilana Lopes Baratella da Cunha Camargo
    Department of Bacteriology, Faculty of Medicine, Juntendo University, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Antimicrob Agents Chemother 52:4289-99. 2008
    In order to better understand the mechanism of daptomycin resistance, we generated a daptomycin-nonsusceptible derivative strain, strain 10*3d1 (MIC = 3...
  26. doi Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians
    Theodoros Kelesidis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    Clin Infect Dis 52:228-34. 2011
    b>Daptomycin is the only antibiotic with in vitro bactericidal activity against vancomycin-resistant Enterococcus (VRE) that is approved by the Food and Drug Administration (FDA)...
  27. ncbi Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
    G L French
    Department of Infection, King s College London, St Thomas Hospital, London SE1 7EH, UK
    J Antimicrob Chemother 58:1107-17. 2006
    ..b>Daptomycin, the first of the cyclic lipopeptides, shows rapid bactericidal activity against S...
  28. doi Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008)
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Diagn Microbiol Infect Dis 65:158-62. 2009
    ..to 2008 in hospitals located in the United States were tested by reference broth microdilution methods against daptomycin and comparison agents. Methicillin (oxacillin) resistance rates were 55.9% and 74...
  29. pmc Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm
    Issam Raad
    The University of Texas M D Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, TX 77030, USA
    Antimicrob Agents Chemother 51:1656-60. 2007
    ..In this in vitro study, we investigated the efficacies of the newer antibiotics daptomycin, linezolid, and tigecycline, in comparison with those of vancomycin, minocycline, and rifampin, against ..
  30. pmc Intermediate vancomycin susceptibility in a community-associated MRSA clone
    Christopher J Graber
    Division of Infectious Diseases, University of California, San Francisco General Hospital, 94110, USA
    Emerg Infect Dis 13:491-3. 2007
    ..Staphylococcus aureus (MRSA) with intermediate susceptibility to vancomycin and reduced susceptibility to daptomycin. The strain was isolated from the bone of a 56-year-old man with lumbar osteomyelitis after a 6-week treatment ..
  31. pmc Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo
    Elizabeth C Weiss
    Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Antimicrob Agents Chemother 53:4096-102. 2009
    ..sarA) has an impact on the susceptibility of established Staphylococcus aureus biofilms to treatment with daptomycin in vivo...
  32. ncbi Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals
    Helio S Sader
    JMI Laboratories, North Liberty, IA, USA
    J Antimicrob Chemother 64:1024-8. 2009
    The bactericidal activities of vancomycin and daptomycin were evaluated in a large collection of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia strains from nine major USA medical centres.
  33. ncbi Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections
    Friederike Traunmüller
    Department of Surgery, Division of Plastic Surgery, Medical University of Graz, Auenbruggerplatz 29, A 8036 Graz, Austria
    J Antimicrob Chemother 65:1252-7. 2010
    In the attempt to overcome increasing glycopeptide- and methicillin-resistant soft tissue infections, daptomycin is presently considered as an attractive alternative to the class of glycopeptides...
  34. doi In vitro activity of daptomycin, linezolid and rifampicin on Staphylococcus epidermidis biofilms
    Bruna Leite
    IBB Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710 057 Braga, Portugal
    Curr Microbiol 63:313-7. 2011
    ..b>Daptomycin and linezolid belong to the novel antibiotic therapies that are active against gram-positive cocci...
  35. pmc Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin
    Anne Kathrin John
    Infectious Diseases Service, Department of Internal Medicine, University Hospital and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Antimicrob Agents Chemother 53:2719-24. 2009
    ..We compared the activity of daptomycin (alone and with rifampin [rifampicin]) with the activities of other antimicrobial regimens against MRSA ATCC ..
  36. pmc Clinical experience with daptomycin in Europe: the first 2.5 years
    Armando Gonzalez-Ruiz
    Microbiology Department, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK
    J Antimicrob Chemother 66:912-9. 2011
    To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes.
  37. pmc Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach
    Adrien Fischer
    Genomic Research Laboratory, University Hospitals of Geneva and University of Geneva, Geneva, Switzerland
    J Antimicrob Chemother 66:1696-711. 2011
    The development of daptomycin resistance in Staphylococcus aureus is associated with clinical treatment failures. The mechanism(s) of such resistance have not been clearly defined.
  38. pmc Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vi
    Kerry L LaPlante
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:2156-62. 2008
    ..45 to 1.3 logs). Overall, administration of daptomycin followed by vancomycin demonstrated the most significant kill against all strains in both models...
  39. pmc Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis
    Anna Barbara Hachmann
    Department of Microbiology, Wing Hall, Cornell University, Ithaca, NY 14853 8101, USA
    Antimicrob Agents Chemother 55:4326-37. 2011
    b>Daptomycin (DAP) is a cyclic lipopeptide that disrupts the functional integrity of the cell membranes of Gram-positive bacteria in a Ca(2+)-dependent manner...
  40. ncbi Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis
    Mark Bounthavong
    Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, USA
    Value Health 14:631-9. 2011
    ....
  41. doi High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study
    Ravina Kullar
    Anti Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA
    Pharmacotherapy 31:527-36. 2011
    To evaluate the clinical response and safety of high-dose daptomycin for treatment of complicated gram-positive infections.
  42. ncbi Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry
    J A Crompton
    Cubist Pharmaceuticals, Lexington, MA 02421, USA
    J Chemother 21:414-20. 2009
    ..Limited data is available describing the long-term safety and efficacy of daptomycin. the safety population was drawn from CORE 2005 and 2006, a retrospective, observational, multicenter study...
  43. doi High-dose daptomycin in documented Staphylococcus aureus infections
    Matteo Bassetti
    Infectious Diseases Division, San Martino Hospital and University of Genoa School of Medicine, Genoa, Italy
    Int J Antimicrob Agents 36:459-61. 2010
    b>Daptomycin is approved at a dose of 4-6 mg/kg/day for the treatment of complicated skin and soft-tissue infection and Staphylococcus aureus bloodstream infection...
  44. pmc Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin
    Manjunath P Pai
    College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131 0001, USA
    Antimicrob Agents Chemother 51:2741-7. 2007
    The present study characterized the single-dose pharmacokinetics of daptomycin dosed as 4 mg/kg of total body weight (TBW) in seven morbidly obese and seven age-, sex-, race-, and serum creatinine-matched healthy subjects...
  45. ncbi In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium
    Laura A Jevitt
    Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
    Microb Drug Resist 9:389-93. 2003
    We assessed the in vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin (QD) against a contemporary challenge panel of 88 staphylococcal and 90 enterococcal isolates...
  46. ncbi LC-MS/MS characterization of phospholipid content in daptomycin-susceptible and -resistant isolates of Staphylococcus aureus with mutations in mprF
    Aileen Rubio
    Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA
    Mol Membr Biol 29:1-8. 2012
    b>Daptomycin (DAP) is a cyclic lipopeptide antibiotic used for the treatment of certain Staphylococcus aureus infections. Although rare, strains have been isolated that are DAP resistant...
  47. doi Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study
    Carol L Moore
    Department of Internal Medicine, Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA
    Clin Infect Dis 54:51-8. 2012
    ..Consensus guidelines recommend considering use of alternative agents for infections involving a higher vancomycin MIC, despite few data to support this approach...
  48. pmc Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    C Garrigós
    Infectious Diseases Service, Hospital Universitari de Bellvitge, Feixa Llarga s n, L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Antimicrob Agents Chemother 54:5251-6. 2010
    ..The aim of this study was to evaluate the efficacies of daptomycin at usual and high doses (equivalent to 6 and 10 mg/kg of body weight/day, respectively, in humans) and in ..
  49. pmc Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
    O Murillo
    Laboratory of Experimental Infection, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Feixa Llarga s n, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Antimicrob Agents Chemother 53:4252-7. 2009
    Since the currently approved dose of daptomycin (6 mg/kg of body weight/day) has been associated with clinical failures and resistance development, higher doses for some difficult-to-treat infections are being proposed...
  50. doi Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years
    Maria D Appleman
    Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Diagn Microbiol Infect Dis 66:441-4. 2010
    We investigated vancomycin and daptomycin efficacy for Staphylococcus aureus isolates at our institution by testing 221 methicillin-sensitive and 299 methicillin-resistant isolates recovered from serious infections between 1979 and 2007 ..
  51. ncbi Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis
    Mark S Rouse
    Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Antimicrob Chemother 57:301-5. 2006
    ..b>Daptomycin is a cyclic lipopeptide anti-infective with activity against MRSA, approved for treatment of complicated skin ..
  52. doi Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus
    Esteban Nannini
    Division of Infectious Diseases, School of Medicine, Universidad Nacional de Rosario, Rosario, Argentina
    Curr Opin Pharmacol 10:516-21. 2010
    ..Nonsusceptibility to daptomycin has been associated with changes in the structure and function of the cell envelope and surface charge...
  53. pmc Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")
    Soo Jin Yang
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, RB 2, Rm 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 54:3161-9. 2010
    In vivo development of daptomycin resistance (DAPr) among Staphylococcus aureus strains, especially methicillin-resistant S. aureus (MRSA) strains, in conjunction with clinical treatment failures, has emerged as a major problem...
  54. pmc Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations
    Warren E Rose
    Department of Pharmacy Practice, Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit Receiving Hospital, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 52:3061-7. 2008
    ..We evaluated the impact of simulated standard- and high-dose daptomycin in combination with gentamicin or rifampin against daptomycin-susceptible and nonsusceptible matched strains of ..
  55. ncbi Daptomycin: a review 4 years after first approval
    Robert Sauermann
    Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Medical University of Vienna, Vienna, Austria
    Pharmacology 81:79-91. 2008
    b>Daptomycin is the first approved member of a new class of antibiotics, namely the cyclic lipopeptides. Daptomycin has rapid bactericidal activity against Gram-positive pathogens...
  56. pmc Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy
    Fred C Tenover
    Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30333, USA
    Int J Antimicrob Agents 33:564-8. 2009
    ..aureus (MRSA) bacteraemia developed endocarditis, failed a second course of vancomycin and then failed daptomycin therapy...
  57. pmc Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model
    Molly Steed
    Anti Infective Research Laboratory, School of Medicine, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 55:3522-6. 2011
    ..potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections...
  58. ncbi Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis
    M Lefebvre
    Universite de Nantes, Faculte de Medecine, EA3826, 1 rue Gaston Veil, F 44035 Nantes, France
    Int J Antimicrob Agents 36:542-4. 2010
    b>Daptomycin exhibits rapid bactericidal activity against Gram-positive organisms, including meticillin-resistant Staphylococcus aureus (MRSA). Daptomycin in combination with rifampicin needs to be assessed in bone infection...
  59. pmc Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations
    Molly E Steed
    Anti Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201, USA
    Antimicrob Agents Chemother 54:5187-92. 2010
    Reduced susceptibility to daptomycin has been reported in patients with infections due to methicillin-resistant Staphylococcus aureus (MRSA)...
  60. doi Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic
    Sara E Cosgrove
    Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Clin Infect Dis 48:713-21. 2009
    ..This study evaluated the association between this practice and nephrotoxicity...
  61. pmc Daptomycin in experimental murine pneumococcal meningitis
    Barry B Mook-Kanamori
    Division of Infectious Disease, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN, USA
    BMC Infect Dis 9:50. 2009
    b>Daptomycin, a lipopeptide antibiotic, could be an alternative to vancomycin for treatment of pneumococcal meningitis...
  62. doi Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy
    Pamela A Moise
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    Ann Pharmacother 43:1211-9. 2009
    b>Daptomycin is approved for the treatment of skin and skin-structure infections (4 mg/kg) and Staphylococcus aureus bacteremia, including right-sided endocarditis (6 mg/kg)...
  63. doi Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE)
    John F Mohr
    Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Int J Antimicrob Agents 33:543-8. 2009
    ..Studies in vitro as well as animal and case studies suggest that daptomycin may be effective in enterococcal infections...
  64. doi Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program
    D A Figueroa
    Department of Pharmacy, New York Hospital Queens, Flushing, New York 11355, USA
    Clin Infect Dis 49:177-80. 2009
    There are limited safety data for high-dose and long-term daptomycin treatment (16mg/kg administered for >or=14 days). We present our experience in 61 patients.
  65. pmc A potential role for daptomycin in enterococcal infections: what is the evidence?
    Rafael Canton
    Servicio de Microbiologia, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS, Madrid, Spain
    J Antimicrob Chemother 65:1126-36. 2010
    ..b>Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections...
  66. doi Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
    Richard H Baltz
    Discovery Biology, Cubist Pharmaceuticals, Inc, 65 Hayden Avenue, Lexington, MA 02421, USA
    Curr Opin Chem Biol 13:144-51. 2009
    b>Daptomycin is a lipopeptide antibiotic used clinically to treat infections caused by Gram-positive bacteria. Laboratory studies have shown that Staphylococcus aureus resistance to daptomycin occurs stepwise and slowly...
  67. doi Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate
    Madhukiran H Murthy
    Department of Internal Medicine and Infectious Disease, University of Nebraska Medical Center, Omaha, USA
    J Med Microbiol 57:1036-8. 2008
    b>Daptomycin is a novel bactericidal agent active against Gram-positive pathogens including meticillin-resistant Staphylococcus aureus (MRSA)...
  68. pmc Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006
    Helio S Sader
    JMI Laboratories, North Liberty, IA 52317, USA
    Antimicrob Agents Chemother 53:4127-32. 2009
    ..We evaluated the possible occurrence of MIC creep when testing vancomycin and daptomycin against methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) by using precise incremental reference ..
  69. pmc Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis
    Francisco M Marty
    Division of Infectious Diseases, Brigham and Women s Hospital, 75 Francis Street, PBB A4, Boston, MA 02115, USA
    J Clin Microbiol 44:595-7. 2006
    The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis...
  70. pmc Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus
    Kenneth H Rand
    Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida 32610, USA
    Antimicrob Agents Chemother 48:2871-5. 2004
    We previously observed marked synergy between daptomycin and both rifampin and ampicillin against vancomycin-resistant enterococci (VRE)...
  71. pmc Resistance studies with daptomycin
    J A Silverman
    Cubist Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    Antimicrob Agents Chemother 45:1799-802. 2001
    We studied the in vitro emergence of resistance to daptomycin using three methods: spontaneous resistance incidence, serial passage in the presence of increasing drug concentrations, and chemical mutagenesis...
  72. ncbi Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Vance G Fowler
    Duke University Medical Center, Durham, NC 27710, USA
    N Engl J Med 355:653-65. 2006
    ..Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed...
  73. ncbi Clinical experience with daptomycin for the treatment of patients with osteomyelitis
    Kenneth C Lamp
    Cubist Pharmaceuticals, Inc, Lexington, Massachusetts, USA
    Am J Med 120:S13-20. 2007
    Data from a registry were analyzed to describe the clinical experience with daptomycin (Cubicin; Cubist Pharmaceuticals, Inc., Lexington, MA) for the treatment of patients with osteomyelitis...
  74. pmc Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains
    Soo Jin Yang
    LA Biomedical Research Institute at Harbor UCLA, 1124 West Carson Street, RB 2, Rm 230, Torrance, CA 90502, USA
    Antimicrob Agents Chemother 53:2636-7. 2009
    ..strains to study (i) regulation of mprF-mediated phosphatidylglycerol lysinylation in the contexts of in vitro daptomycin (DAP) nonsuceptibility and (ii) the role of mprF mutation in endovascular virulence...
  75. pmc Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
    Abhijit Chakraborty
    Novartis Institutes for BioMedical Research, East Hanover, NJ, USA
    J Antimicrob Chemother 64:151-8. 2009
    ..separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative ..
  76. pmc Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis
    Kerry L LaPlante
    University of Rhode Island, Department of Pharmacy Practice, Providence, RI 02908, USA
    Antimicrob Agents Chemother 53:3880-6. 2009
    ..Staphylococcus aureus (MRSA) isolates obtained from patients with IE and to evaluate the in vitro activities of daptomycin and vancomycin alone and in combination with rifampin (rifampicin) or gentamicin while monitoring the isolates ..
  77. ncbi Mechanistic and structural basis of stereospecific Cbeta-hydroxylation in calcium-dependent antibiotic, a daptomycin-type lipopeptide
    Matthias Strieker
    Department of Chemistry Biochemistry, Philipps University of Marburg, Marburg, Germany
    ACS Chem Biol 2:187-96. 2007
    Non-ribosomally synthesized lipopeptide antibiotics of the daptomycin type are known to contain unnatural beta-modified amino acids, which are essential for bioactivity...
  78. pmc Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm
    Jorge Parra-Ruiz
    Wayne State University, Anti Infective Research Laboratory, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 54:4329-34. 2010
    ..vancomycin (VAN) plus rifampin (RIF), moxifloxacin (MOX), and high doses (10 mg/kg of body weight/day) of daptomycin (DAP) alone or combined with RIF or clarithromycin (CLA)...
  79. doi Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study
    Jan T Kielstein
    Department of Nephrology and Hypertension, Medical School Hannover, Germany
    Nephrol Dial Transplant 25:1537-41. 2010
    b>Daptomycin is a new intravenous cyclic lipopeptide antibiotic, licensed for the treatment of complicated skin and soft tissue infections caused by Gram-positive organisms including both susceptible and resistant strains of Staphylococcus ..
  80. ncbi The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
    Robert D Arbeit
    Cubist Pharmaceuticals, Lexington, Massachusetts 02421, USA
    Clin Infect Dis 38:1673-81. 2004
    b>Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and ..
  81. ncbi Daptomycin-resistant Enteroccoccus faecium in a patient with no prior exposure to daptomycin
    M H Fraher
    J Hosp Infect 65:376-8. 2007
  82. ncbi Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia
    A Mangili
    Division of Geographic Medicine and Infectious Diseases, Department of Medicine, Tufts New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA
    Clin Infect Dis 40:1058-60. 2005
    We describe a patient who developed daptomycin-resistant, methicillin-resistant Staphylococcus aureus (MRSA) during an episode of presumed septic thrombophlebitis of the portal vein...
  83. pmc De novo daptomycin nonsusceptibility in a clinical isolate
    Emil P Lesho
    J Clin Microbiol 44:673. 2006
  84. pmc In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates
    Louis Saravolatz
    St John Hospital and Medical Center, 19251 Mack Ave, Suite 333, Detroit, MI 48236, USA
    Antimicrob Agents Chemother 54:3027-30. 2010
    ..aureus (VISA), vancomycin-resistant S. aureus (VRSA), heteroresistant VISA (hVISA), and daptomycin-nonsusceptible S. aureus (DNSSA) isolates...
  85. pmc The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion
    Christoph M Ernst
    Cellular and Molecular Microbiology Division, Interfaculty Institute of Microbiology and Infection Medicine, University of Tubingen, Tubingen, Germany
    PLoS Pathog 5:e1000660. 2009
    ..a crucial role in Staphylococcus aureus virulence and it is involved in resistance to the CAMP-like antibiotic daptomycin. MprF is a large membrane protein that modifies the anionic phospholipid phosphatidylglycerol with l-lysine, ..
  86. ncbi Daptomycin for the treatment of surgical site infections
    Ronald S Chamberlain
    Department of Surgery, St Barnabas Medical Center, Livingston, NJ 07039, USA
    Surgery 146:316-24. 2009
    ..The increasing frequency of methicillin-resistant Staphylococcus aureus (MRSA) as a cause of surgical site infections, and decreased susceptibility to vancomycin, highlight the need for alternative therapies...
  87. ncbi Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus
    Brian Quinn
    Public Health Research Institute and Department of Microbiology and Molecular Genetics, UMDNJ New Jersey Medical School, 225 Warren Street, Newark, NJ 07103, USA
    J Antimicrob Chemother 60:1380-3. 2007
    ..Large bacterial inocula known to reduce susceptibility have not been studied for effects on MPC determination...
  88. pmc Mechanisms of resistance to daptomycin in Enterococcus faecium
    Clemente I Montero
    Microbiology Service, Department of Laboratory Medicine, Warren G Magnuson Clinical Center, National Institutes of Health, US Department of Health and Human Services, 10 Center Drive, MSC 1508, Bethesda, Maryland 20892 1508, USA
    Antimicrob Agents Chemother 52:1167-70. 2008
    In this study, we investigated the clonal emergence of daptomycin-resistant Enterococcus faecium strains isolated from a patient with leukocyte adhesion deficiency syndrome...
  89. ncbi Daptomycin in the treatment of patients with infective endocarditis: experience from a registry
    Donald P Levine
    Wayne State University, University Health Center, Detroit, Michigan, USA
    Am J Med 120:S28-33. 2007
    b>Daptomycin (Cubicin; Cubist Pharmaceuticals, Inc...
  90. pmc Daptomycin in bone and joint infections: a review of the literature
    Dennis A K Rice
    St Joseph s Candler Health System, Savannah, GA, USA
    Arch Orthop Trauma Surg 129:1495-504. 2009
    To review the pharmacology, pharmacokinetics, efficacy, and safety of daptomycin, a novel antibiotic for the treatment of bone and joint infections, a literature search of relevant articles was conducted.
  91. doi Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus
    Joanne Karen Hobbs
    Antimicrobial Research Centre and Institute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK
    J Antimicrob Chemother 62:1003-8. 2008
    The proposed lethal action of daptomycin on Staphylococcus aureus results from the loss of K(+) and membrane depolarization. However, whether these events alone cause cell death has been questioned...
  92. ncbi Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus
    Pierre Vaudaux
    Division of Infectious Diseases, Geneva University Hospital, CH 1211 Geneva 14, Switzerland
    J Antimicrob Chemother 52:89-95. 2003
    The therapeutic activity of daptomycin was compared with that of vancomycin in a rat model of subcutaneously implanted tissue cages chronically infected with strain Rev1, a spontaneous methicillin-susceptible revertant of the methicillin-..
  93. pmc Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria
    Lawrence I Mortin
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 51:1787-94. 2007
    The rising rates of antibiotic resistance accentuate the critical need for new antibiotics. Daptomycin is a new antibiotic with a unique mode of action and a rapid in vitro bactericidal effect against gram-positive organisms...
  94. pmc Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm
    Philip S Stewart
    Center for Biofilm Engineering, Department of Chemical and Biological Engineering, Montana State University, Bozeman, MT 59717 3980, USA
    Antimicrob Agents Chemother 53:3505-7. 2009
    Fluorescently tagged daptomycin accessed the interior of Staphylococcus epidermidis biofilm cell clusters within minutes. The diffusion coefficient of daptomycin in the biofilm was 28% of its value in pure water...
  95. doi Effects of daptomycin in combination with other antimicrobial agents: a review of in vitro and animal model studies
    Judith N Steenbergen
    Cubist Pharmaceuticals Inc, Lexington, MA 02421, USA
    J Antimicrob Chemother 64:1130-8. 2009
    This review summarizes the in vitro and animal model data available on antibiotic combinations with daptomycin. The majority of studies focus on the clinically relevant combinations of daptomycin with rifampicin or with gentamicin...
  96. pmc Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF
    Satish K Pillai
    Department of Infectious Disease, Cleveland Clinic Foundation, Mailstop S32, Cleveland, OH 44195, USA
    Antimicrob Agents Chemother 51:2223-5. 2007
    A previous study documented the presence of mutations in mprF that accompanied the loss of daptomycin susceptibility among Staphylococcus aureus isolates following exposure to the drug...
  97. pmc Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy
    James S Lewis
    Antimicrob Agents Chemother 49:1664-5. 2005
  98. pmc Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection
    A Louie
    Division of Infectious Diseases, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 45:845-51. 2001
    b>Daptomycin is a lipopeptide antibiotic with activity against gram-positive bacteria, including Staphylococcus aureus. We defined the pharmacodynamic parameters that determine the activity of daptomycin for S...
  99. pmc Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin
    Anna Barbara Hachmann
    Department of Microbiology, Wing Hall, Cornell University, Ithaca, New York 14853 8101, USA
    Antimicrob Agents Chemother 53:1598-609. 2009
    b>Daptomycin is the first of a new class of cyclic lipopeptide antibiotics used against multidrug-resistant, gram-positive pathogens...
  100. pmc Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus
    Aileen Rubio
    Cubist Pharmceuticals, Lexington, MA 02421, USA
    Antimicrob Agents Chemother 55:364-7. 2011
    Mutations in mprF have been shown to result in reduced susceptibility to daptomycin and other cationic antibacterials...
  101. doi Effects of tigecycline and daptomycin on murine gut colonization by Candida albicans
    George Samonis
    Division of Medicine, University of Crete, Crete, Greece
    Mycoses 51:324-7. 2008
    ..Both groups were subsequently given tigecycline or daptomycin or normal saline subcutaneously for 10 days...

Research Grants50

  1. Clinical Research Training in Infectious Diseases
    David Snydman; Fiscal Year: 2007
    ..The goal of this training program will be to develop independent infectious diseases clinical research investigators highly skilled in clinical research methodologies and application. ..
  2. CYTOMETRY-AIDED DEVELOPMENT OF ANTIMICROBIAL AGENTS
    Howard Shapiro; Fiscal Year: 2001
    ..measurement of tetracycline uptake and efflux in bacteria, and detection of effects of tetracyclines and daptomycin on membrane potential, pH, and permeability...
  3. Role of Membrane Fluidity in S. aureus Antimicrobial Susceptibility
    BRIAN WILKINSON; Fiscal Year: 2009
    ..This will be studied in pine oil cleaner- and daptomycin-resistant strains...
  4. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2003
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  5. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2005
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  6. Modification of daptomycin by combinatorial biosynthesis
    Paul Brian; Fiscal Year: 2004
    The antibiotic daptomycin is produced by the Gram-positive bacterium Streptomyces roseosporus and is the first in a new class of investigational drugs called lipopeptides that is being developed by Cubist for the treatment of serious and ..
  7. Development of furanones for treatment of anthrax
    Martin Blaser; Fiscal Year: 2005
    ..Ciprofloxacin or daptomycin will be used as comparitors, and synergies with the furanones explored as well...
  8. Structure activity relationships around lipopeptides
    Paul Brian; Fiscal Year: 2003
    ..The most notable lipopeptide from the 10-membered ring group is daptomycin that is currently progressing through clinical trials...
  9. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    Sara Cosgrove; Fiscal Year: 2009
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  10. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    Sara Cosgrove; Fiscal Year: 2008
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  11. Reducing Antimicrobial Use Associated with Ventilator Associated Pneumonia and Ca
    SARA ELIZABETH COSGROVE; Fiscal Year: 2010
    ..We hypothesize that this approach will enhance appropriate use of antimicrobials for both VAP and CAUTI and improve patient outcomes by reducing the known sequelae of antimicrobial overuse. ..
  12. Novel antibacterial agents for treatment of Tularemia
    Nachum Kaplan; Fiscal Year: 2004
    ..tularensis microbiological data and animal model data to warrant inclusion of the information on the product label as a narrow spectrum agent that could be used in the event of a F. tularensis release. ..
  13. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2004
    ..aureus strains for killing, as well as to circumvent innate homeostatic mechanisms used by the organism for survival. ..
  14. Staphylococcal Adaptations to Platelet Microbicidal Protein
    Arnold Bayer; Fiscal Year: 2007
    ..This may enable design of new of strategies to kill such bacteria. ..
  15. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2003
    ..aureus strains for killing, as well as to circumvent innate homeostatic mechanisms used by the organism for survival. ..
  16. DNA segregation during Bacillus growth and development
    JOSEPH POGLIANO; Fiscal Year: 2008
    ..These studies will allow the development of better genetic tools and plasmid vectors useful for manipulating many Bacillus species. ..
  17. Cytology and function of ParA in E. coli
    JOSEPH A POGLIANO; Fiscal Year: 2010
    ..The findings from this analysis of a representative ParAB plasmid partitioning system should have wide implications for our understanding of plasmid and chromosome segregation. ..
  18. DNA segregation during Bacillus growth and development
    JOSEPH POGLIANO; Fiscal Year: 2009
    ..These studies will allow the development of better genetic tools and plasmid vectors useful for manipulating many Bacillus species. ..
  19. Cytology and function of ParA in E. coli
    JOSEPH POGLIANO; Fiscal Year: 2009
    ..The findings from this analysis of a representative ParAB plasmid partitioning system should have wide implications for our understanding of plasmid and chromosome segregation. ..
  20. DNA segregation during Bacillus growth and development
    JOSEPH POGLIANO; Fiscal Year: 2006
    ..These studies will allow the development of better genetic tools and plasmid vectors useful for manipulating many Bacillus species. ..
  21. DNA segregation during Bacillus growth and development
    JOSEPH A POGLIANO; Fiscal Year: 2010
    ..These studies could therefore help identify targets for new narrow spectrum antibiotics, since blocking plasmid stability will in certain infections decrease pathogenicity. ..
  22. Staphylococcal Adaptations to Platelet Microbicidal Protein
    Arnold S Bayer; Fiscal Year: 2010
    ..The research in this proposal seeks to understand how bacteria can withstand the exposures to an important part of the host defense system (natural peptide antibiotics). This may enable design of new of strategies to kill such bacteria. ..
  23. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2006
    ..aureus strains for killing, as well as to circumvent innate homeostatic mechanisms used by the organism for survival. ..
  24. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2005
    ..aureus strains for killing, as well as to circumvent innate homeostatic mechanisms used by the organism for survival. ..
  25. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 1999
    ..tPMP will also serve as a design template for development of synthetic congeners with potent antimicrobial activity. ..
  26. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2002
    ..aureus strains for killing, as well as to circumvent innate homeostatic mechanisms used by the organism for survival. ..
  27. STAPHYLOCIDAL MECHANISM OF PLATELET MICROBICIDAL PROTEIN
    Arnold Bayer; Fiscal Year: 2000
    ..tPMP will also serve as a design template for development of synthetic congeners with potent antimicrobial activity. ..
  28. Staphylococcal Adaptations to Platelet Microbicidal Protein
    Arnold Bayer; Fiscal Year: 2009
    ..The research in this proposal seeks to understand how bacteria can withstand the exposures to an important part of the host defense system (natural peptide antibiotics). This may enable design of new of strategies to kill such bacteria. ..
  29. Staphylococcal Adaptations to Platelet Microbicidal Protein
    Arnold Bayer; Fiscal Year: 2008
    ..This may enable design of new of strategies to kill such bacteria. ..
  30. DNA segregation during Bacillus growth and development
    JOSEPH POGLIANO; Fiscal Year: 2007
    ..These studies will allow the development of better genetic tools and plasmid vectors useful for manipulating many Bacillus species. ..
  31. DNA segregation during Bacillus growth and development
    JOSEPH POGLIANO; Fiscal Year: 2007
    ..These studies will allow the development of better genetic tools and plasmid vectors useful for manipulating many Bacillus species. ..
  32. Genetic Basis of Virulence of Community MRSA Clone USA300
    Henry F Chambers; Fiscal Year: 2010
    ..By knocking each of these genes out and testing for loss of virulence, we hope to learn which genes code for virulence. Once these genes are identified, strategies to block their effects may be developed. ..
  33. B-lactam mediated SOS response and expression of resistance in clinical MRSA
    Adriana E Rosato; Fiscal Year: 2010
    ....
  34. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2000
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  35. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2002
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  36. Genetic Basis of Virulence of Community MRSA Clone USA300
    Henry Chambers; Fiscal Year: 2009
    ..By knocking each of these genes out and testing for loss of virulence, we hope to learn which genes code for virulence. Once these genes are identified, strategies to block their effects may be developed. ..
  37. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2003
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  38. Clinical Research Training in Infectious Diseases
    David Snydman; Fiscal Year: 2008
    ..The goal of this training program will be to develop independent infectious diseases clinical research investigators highly skilled in clinical research methodologies and application. ..
  39. Evaluating Trichophyton tonsurans Carriage and Infection
    Susan Abdel Rahman; Fiscal Year: 2006
    ..abstract_text> ..
  40. Mentored Patient-Oriented Research Careeer Development Award
    Debra Poutsiaka; Fiscal Year: 2007
    ..abstract_text> ..
  41. Intra-species regulatory functions of fsr
    Satish Pillai; Fiscal Year: 2004
    ..abstract_text> ..
  42. PENICILLIN INTERACTIVE PROTEINS OF STAPHYLOCOCCUS AUREUS
    Henry Chambers; Fiscal Year: 2001
    ..To augment information about where PBPs localize, when they are expressed during the cell cycle will be determined by Northern blotting. ..
  43. Mentored Patient-Oriented Research Careeer Development Award
    Debra Poutsiaka; Fiscal Year: 2008
    ..abstract_text> ..
  44. Genetic Analysis of HIV Complications
    Alexandra Mangili; Fiscal Year: 2007
    ....
  45. Genetic Analysis of HIV Complications
    Alexandra Mangili; Fiscal Year: 2008
    ....
  46. Enterococcus faecium virulence: A molecular and therapeutic approach
    Cesar Arias; Fiscal Year: 2008
    ..A translational approach using the mentor's laboratory established animal models (mouse peritonitis and rat infective endocarditis) will be utilized to explore therapeutic approaches. [unreadable] [unreadable] [unreadable]..
  47. FUNGAL PROTEIN/GLYCOPROTEIN EXPRESSION IN TINEA CAPITIS
    Susan Abdel Rahman; Fiscal Year: 2003
    ..abstract_text> ..
  48. B-lactam mediated SOS response and expression of resistance in clinical MRSA
    Adriana E Rosato; Fiscal Year: 2010
    ....